239 related articles for article (PubMed ID: 37424386)
21. Targeting G1/S phase cell-cycle genomic alterations and accompanying co-alterations with individualized CDK4/6 inhibitor-based regimens.
Kato S; Okamura R; Adashek JJ; Khalid N; Lee S; Nguyen V; Sicklick JK; Kurzrock R
JCI Insight; 2021 Jan; 6(1):. PubMed ID: 33427211
[TBL] [Abstract][Full Text] [Related]
22. Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies.
Kwapisz D
Breast Cancer; 2018 Sep; 25(5):506-516. PubMed ID: 29700711
[TBL] [Abstract][Full Text] [Related]
23. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
[TBL] [Abstract][Full Text] [Related]
24. Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review.
Di Lauro V; Barchiesi G; Martorana F; Zucchini G; Muratore M; Fontanella C; Arpino G; Del Mastro L; Giuliano M; Puglisi F; De Laurentiis M
ESMO Open; 2022 Dec; 7(6):100629. PubMed ID: 36399953
[TBL] [Abstract][Full Text] [Related]
25. Cyclin D-CDK4/6 functions in cancer.
Gao X; Leone GW; Wang H
Adv Cancer Res; 2020; 148():147-169. PubMed ID: 32723562
[TBL] [Abstract][Full Text] [Related]
26. CDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis.
Onesti CE; Jerusalem G
Expert Rev Anticancer Ther; 2021 Mar; 21(3):283-298. PubMed ID: 33233970
[No Abstract] [Full Text] [Related]
27. Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer.
Martin M; Garcia-Saenz JA; Manso L; Llombart A; Cassinello A; Atienza M; Ringeisen F; Ciruelos E
Future Oncol; 2020 Nov; 16(33):2763-2778. PubMed ID: 32781837
[TBL] [Abstract][Full Text] [Related]
28. A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib.
Chong QY; Kok ZH; Bui NL; Xiang X; Wong AL; Yong WP; Sethi G; Lobie PE; Wang L; Goh BC
Pharmacol Res; 2020 Jun; 156():104686. PubMed ID: 32068118
[TBL] [Abstract][Full Text] [Related]
29. Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: study protocol for a randomized controlled trial.
van Ommen-Nijhof A; Konings IR; van Zeijl CJJ; Uyl-de Groot CA; van der Noort V; Jager A; Sonke GS;
BMC Cancer; 2018 Nov; 18(1):1146. PubMed ID: 30458732
[TBL] [Abstract][Full Text] [Related]
30. CDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update.
O'Sullivan CC
Expert Opin Pharmacother; 2016 Aug; 17(12):1657-67. PubMed ID: 27322766
[TBL] [Abstract][Full Text] [Related]
31. The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis.
Lee KWC; Lord S; Finn RS; Lim E; Martin A; Loi S; Lynch J; Friedlander M; Lee CK
Breast Cancer Res Treat; 2019 Feb; 174(1):271-278. PubMed ID: 30465154
[TBL] [Abstract][Full Text] [Related]
32. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
Roskoski R
Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
[TBL] [Abstract][Full Text] [Related]
33. SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy).
Edelman MJ; Redman MW; Albain KS; McGary EC; Rafique NM; Petro D; Waqar SN; Minichiello K; Miao J; Papadimitrakopoulou VA; Kelly K; Gandara DR; Herbst RS
J Thorac Oncol; 2019 Oct; 14(10):1853-1859. PubMed ID: 31302234
[TBL] [Abstract][Full Text] [Related]
34. Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women.
Gupta N; Gupta D; Dixit J; Mehra N; Singh A; Krishnamurthy MN; Jyani G; Rajsekhar K; Kalaiyarasi JP; Roy PS; Malik PS; Mathew A; Malhotra P; Gupta S; Kumar L; Kataki A; Prinja S
Appl Health Econ Health Policy; 2022 Jul; 20(4):609-621. PubMed ID: 35534752
[TBL] [Abstract][Full Text] [Related]
35. Mechanisms of therapeutic CDK4/6 inhibition in breast cancer.
Scott SC; Lee SS; Abraham J
Semin Oncol; 2017 Dec; 44(6):385-394. PubMed ID: 29935900
[TBL] [Abstract][Full Text] [Related]
36. Potential biomarkers of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer.
Fang H; Huang D; Yang F; Guan X
Breast Cancer Res Treat; 2018 Apr; 168(2):287-297. PubMed ID: 29236235
[TBL] [Abstract][Full Text] [Related]
37. [18F]-Fluorodeoxyglucose Positron Emission Tomography/CT to Assess the Early Metabolic Response in Patients with Hormone Receptor-Positive HER2-Negative Metastasized Breast Cancer Treated with Cyclin-Dependent 4/6 Kinase Inhibitors.
Seifert R; Küper A; Tewes M; Heuschmid M; Welt A; Fendler WP; Herrmann K; Decker T
Oncol Res Treat; 2021; 44(7-8):400-407. PubMed ID: 34102639
[TBL] [Abstract][Full Text] [Related]
38. Ribociclib, a selective cyclin D kinase 4/6 inhibitor, inhibits proliferation and induces apoptosis of human cervical cancer in vitro and in vivo.
Xiong Y; Li T; Assani G; Ling H; Zhou Q; Zeng Y; Zhou F; Zhou Y
Biomed Pharmacother; 2019 Apr; 112():108602. PubMed ID: 30784916
[TBL] [Abstract][Full Text] [Related]
39. Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcSé-ESMART Trial.
Bautista F; Paoletti X; Rubino J; Brard C; Rezai K; Nebchi S; Andre N; Aerts I; De Carli E; van Eijkelenburg N; Thebaud E; Corradini N; Defachelles AS; Ducassou S; Morscher RJ; Vassal G; Geoerger B
J Clin Oncol; 2021 Nov; 39(32):3546-3560. PubMed ID: 34347542
[TBL] [Abstract][Full Text] [Related]
40. Mechanism of CDK4/6 Inhibitor Resistance in Hormone Receptor-positive Breast Cancer and Alternative Treatment Strategies.
Chang CM; Lam HYP
Anticancer Res; 2023 Dec; 43(12):5283-5298. PubMed ID: 38030174
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]